



MATINS
HEALTHCARE PVT. LTD.

MATINS HEALTHCARE PVT. LTD.

PLOT No - 10, SEC TOR-5, IIE, SIDCUL, HARIDWAR
Mfg. Licence No.: 61/UA/SC/P-2006 & 62/UA/2006

QUALITY CONTROL DEPARTMENT
(FINISHED)

(The Drugs & Cosmetics Act 1940 and the Rules there under)

CERTIFICATE OF ANALYSIS

Product Name	HEALMARYL MV 3.3	A.R. No.	MFGT-231281
Generic Name	Metformin HCl (SR) 500 mg, Glimepiride 3 mg & Voglibose 0.3 mg Tablets	Batch Size	1.0 Lac Tablets
Batch No.	MT-231281	Sample Qty.	100 Tablets
Mfg. Date	10/2023	Sample received date	08/11/2023
Exp. Date	09/2025	Date of Release	09/11/2023

Sr. No.	TESTS	SPECIFICATIONS	RESULTS
1	Description	Yellow/White colour elongated, biconvex, uncoated bilayer tablets	Yellow/White colour elongated, biconvex, uncoated bilayer tablets
2	Identification: By HPLC	The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay.	Complies
3	Average weight	860 mg $\pm$ 5% (817.0 to 903.0 mg)	858.30 mg
4	Uniformity of weight	$\pm$ 5% on average weight	Positive deviation= 1.26% Negative deviation= 1.39%
5	Dissolution for Metformin HCl After 1 st hour After 3 rd hour After 10 th hour	(NMT 40%) (45% to 75%) (NLT 85%)	(22.13% to 32.53%) (51.15% to 61.19%) (90.29% to 99.16%)
6	Assay: Each uncoated bilayer tablet contains:		
	Metformin Hydrochloride IP 500 mg (As Sustained release)	Not less than 90% and not more than 110% (450.0 mg to 550.0 mg)	499.63 mg (99.93%)
	Glimepiride IP 3 mg	Not less than 90% and not more than 110% (2.7 mg to 3.3 mg)	3.03 mg (101.00%)
	Voglibose IP 0.3 mg	Not less than 90% and not more than 110% (0.27 mg to 0.33 mg)	0.302 mg (100.67%)

Remarks: The product complies as per IHS Specification.

09/11/2023
Analyzed by

09/11/2023
Checked by

09/11/2023
Approved by